In rats and minipigs with an obesity-linked form of heart failure, semaglutide cut heart stiffness and scarring without lowering weight. Published in the European Heart Journal.
Recap by typeshit. Full story at Cedars-Sinai.
A short post credits scientists with finding axolotl peptides that kill breast cancer cells. It names no study or team, so treat it as an early claim.
Pratt, a psychology professor who studies the circuits behind food motivation, walks through what neuroscience shows about these drugs.
Lilly's pill had major heart events in 4.2% of patients vs 5.0% on insulin glargine. The Clinical Trial Vanguard argues rivals now need to show benefit, not just safety.
Researchers report that asprosin, a hunger hormone released by fat tissue, stays elevated after weight loss, which could help explain why lost pounds come back.
Medical Xpress reports late stage results for Lilly's triple-action shot in patients with type 2 diabetes.
A clip from a longer interview questions whether patients need to climb to the maximum tirzepatide dose. The full talk is on their podcast.
Loading…